Regeneron to Highlight Pioneering Pipeline Progress Across …
1 day ago · When Regeneron's Co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985.They were the …
Press Releases | Regeneron Pharmaceuticals Inc.
Oct 31, 2024 · Regeneron Reports Third Quarter 2024 Financial and Operating Results. Oct 24. Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria …
Regeneron to Highlight Pioneering Pipeline Progress Across …
1 day ago · --Regeneron Pharmaceuticals, Inc. today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology …
Regeneron to Highlight Pioneering Pipeline Progress Across
1 day ago · Tel: +1 914-847-3482. [email protected]. Company Profile Regeneron Pharmaceuticals, Inc. Industry: Pharmaceuticals Website: Oral presentation shares head-to …
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment ...
1 day ago · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA’s (NASDAQ: SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its …
News Release - Regeneron Pharmaceuticals Inc.
Jan 30, 2024 · Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to …
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met …
Regeneron to Showcase Progress in Advancing Novel …
Apr 24, 2024 · Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO. Oral …
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Oct 31, 2024 · Regeneron (REGN) delivered earnings and revenue surprises of 6.04% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to …
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
2 days ago · Itepekimab (Sanofi/Regeneron Pharmaceuticals), Benralizumab (AstraZeneca), Tezepelumab (Amgen/AstraZeneca), Mepolizumab (GSK), and others shall further create a …
- Some results have been removed